KHK2455 + Avelumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urothelial Carcinoma
Conditions
Urothelial Carcinoma
Trial Timeline
Sep 26, 2019 → Nov 15, 2022
NCT ID
NCT03915405About KHK2455 + Avelumab
KHK2455 + Avelumab is a phase 1 stage product being developed by Kyowa Kirin for Urothelial Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03915405. Target conditions include Urothelial Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03915405 | Phase 1 | Terminated |
Competing Products
20 competing products in Urothelial Carcinoma